Table 5 Carrier frequency of various susceptibility-related factor combinations among patients with lung cancer and healthy controls.
From: KIR-HLA gene diversities and susceptibility to lung cancer
KIR combination | Healthy controls | Lung cancer | Lung cancer versus HC | ||
|---|---|---|---|---|---|
n = 448 | n = 232 | p value | Pc | OR (95% CI) | |
%F (N + /n) | F% (N + /n) | ||||
KIR genotypes | |||||
iKIR > aKIR | 52.2 (234/448) | 64.7 (150/232) | 0.002 | 0.008* | 1.67 (1.2–2.32) |
aKIR > iKIR | 19.4 (87/448) | 13.4 (31/232) | |||
iKIR > 4 | 67.0 (300/448) | 75.0 (174/232) | 0.035 | 0.14* | 1.48 (1.036–2.11) |
aKIR > 4 | 50.0 (224/448) | 40.1 (93/232) | 0.015 | 0.06* | 0.66 (0.48–0.92) |
KIR combined genotypes | |||||
CxTx/2DS2 | 11.1 (50/448) | 20.2 (47/232) | 0.0074 | 0.066** | 1.84 (1.18–2.88) |
CxTx/2DL2 | 12.3 (55/448) | 23.7 (55/232) | 0.0012 | 0.011** | 2.04 (1.34–3.13) |
iKIR > aKIR carriers subgroup | |||||
2DS2 presence | 45.2 (105/232) | 59.3 (89/150) | 0.0087 | 0.078** | 1.76 (1.16–2.67) |
2DL2 presence | 49.1 (114/232) | 66.6 (100/150) | 0.0008 | 0.0072** | 2.05 (1.35–3.17) |
